CJC-1295 without Drug Affinity Complex (Modified GRF 1-29)
A modified growth-hormone-releasing hormone (GHRH) analog, also known as Mod GRF 1-29, studied in preclinical research on GH secretagogue pathways.
Overview
CJC-1295 without DAC — frequently referred to in the literature as Modified GRF (1-29), or Mod GRF 1-29 — is a synthetic analog of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH), modified at several positions to resist enzymatic degradation. Peptide Factory supplies this peptide as a lyophilized powder for laboratory research.
Research Background
Native GHRH(1-29) is rapidly degraded in circulation by dipeptidyl peptidase-4 (DPP-4) and other proteases. The amino acid substitutions in CJC-1295 (no DAC) were designed to confer resistance to this degradation, extending the peptide’s research half-life relative to native GHRH while preserving its receptor-binding profile at the GHRH receptor (GHRHR) on pituitary somatotroph cells.
Studied Applications
Laboratory and preclinical research involving CJC-1295 (no DAC) has focused on:
- GH secretagogue pathway research — in vitro pituitary cell culture and in vivo animal models have been used to characterize dose-response relationships between GHRH receptor agonists and growth hormone/IGF-1 axis activity.
- Synergy research with ghrelin-mimetic peptides — studies combining GHRH analogs with growth hormone secretagogues (e.g., Ipamorelin) have investigated pulsatile GH release mechanisms in animal models.
- Pharmacokinetic comparison research — used as a shorter-acting reference compound against DAC-modified and other long-acting GHRH analogs in half-life and receptor-occupancy studies.
These findings reflect laboratory and animal research; no dosing or human-use guidance is provided.
Storage & Handling
Store lyophilized CJC-1295 (no DAC) at -20°C, protected from light and moisture. See our storage and handling guidance for reconstitution protocols.
References
- Teichman, S. L. et al. “Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295.” J. Clin. Endocrinol. Metab. research literature.
- Ionescu, M. & Frohman, L. A. GHRH analog pharmacokinetics research.
- Walker, R. F. GHRH-based secretagogue research review.
For Research Use Only — Not for Human Consumption.
Frequently Asked
What distinguishes CJC-1295 without DAC from the DAC version?
Does CJC-1295 (no DAC) act directly on the pituitary?
Related Products
For Research Use Only — Not for Human Consumption